arrow_back Back to App

Cancer Drug Parity Act: Equalizing Patient Costs for Oral and IV Cancer Treatments.

This law mandates that group health plans must treat cost-sharing for prescribed oral cancer medications no less favorably than for cancer drugs administered intravenously or by injection by a healthcare provider. This aims to reduce financial barriers, ensuring patients do not face higher deductibles or copayments simply because their treatment is taken in pill form at home. The goal is to improve access to convenient, patient-administered cancer therapies.
Key points
Group health plans must ensure out-of-pocket costs for oral cancer drugs are equal to or lower than costs for IV or injected cancer drugs.
The rule applies to group health plans starting with plan years on or after January 1, 2024.
Insurance plans are prohibited from increasing overall cancer drug costs or reclassifying benefits to circumvent this parity requirement.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_S_2039
Sponsor: Sen. Smith, Tina [D-MN]
Process start date: 2023-06-15
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-09-2025
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Cancer Drug Parity Act of 2023

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_S_2039.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2023-06-15.

What are the main provisions?

Key points include:

  • Group health plans must ensure out-of-pocket costs for oral cancer drugs are equal to or lower than costs for IV or injected cancer drugs.
  • The rule applies to group health plans starting with plan years on or after January 1, 2024.
  • Insurance plans are prohibited from increasing overall cancer drug costs or reclassifying benefits to circumvent this parity requirement.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Smith, Tina [D-MN].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-26.

CATEGORIES

Health